122 related articles for article (PubMed ID: 18418959)
1. [Paying attention to TCM and integrative medicine in treating YMDD mutation of chronic hepatitis B].
Li J
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2008 Jan; 28(1):9-10. PubMed ID: 18418959
[No Abstract] [Full Text] [Related]
2. [Types and emergence time of YMDD motif mutation in hepatitis B virus polymerase gene during lamivudine treatment].
Liang WF; Yang DH; Shen YH; Xie YJ; Zhao NF
Zhonghua Gan Zang Bing Za Zhi; 2003 May; 11(5):302-4. PubMed ID: 12773248
[TBL] [Abstract][Full Text] [Related]
3. [Therapeutic efficacy of combined application of lamivudine and bushen recipe in treating chronic hepatitis B and its influence on YMDD motif].
Zhou F; Wang LT; Chen JJ
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2003 Jun; 23(6):417-20. PubMed ID: 12872391
[TBL] [Abstract][Full Text] [Related]
4. [YMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapy].
Arslan U; Ural O; Findik D
Mikrobiyol Bul; 2008 Jul; 42(3):445-50. PubMed ID: 18822888
[TBL] [Abstract][Full Text] [Related]
5. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
[TBL] [Abstract][Full Text] [Related]
6. Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy.
Lee SH; Kim HS; Byun IS; Jeong SW; Kim SG; Jang JY; Kim YS; Kim BS
J Med Virol; 2012 Feb; 84(2):217-22. PubMed ID: 22170540
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy changes of short-term lamivudine therapy for chronic hepatitis B with emergence of YMDD mutation].
Deng H; Lv Y; Fu J
Zhonghua Gan Zang Bing Za Zhi; 2004 Jun; 12(6):368-9. PubMed ID: 15225437
[TBL] [Abstract][Full Text] [Related]
8. [Detection and analysis of the new kind of G743C and G743A point mutation of HBV P gene in hepatitis B virus infected patients resistant to lamivudine].
Pan XP; Wo JE; Chen Z; Chen F; Liang WF; Liu KZ
Zhonghua Gan Zang Bing Za Zhi; 2003 Oct; 11(10):616-8. PubMed ID: 14572341
[TBL] [Abstract][Full Text] [Related]
9. [YMDD motif and its significance].
Goto T; Kato N; Omata M
Nihon Rinsho; 2004 Aug; 62 Suppl 8():46-50. PubMed ID: 15453283
[No Abstract] [Full Text] [Related]
10. [Effect of a Chinese herbal compound and lamivudine combination therapy on patients with chronic hepatitis B and its influence on YMDD motif mutation].
Tu YY; Qiu HX
Zhonghua Gan Zang Bing Za Zhi; 2005 Dec; 13(12):933, 936. PubMed ID: 16381644
[No Abstract] [Full Text] [Related]
11. Polymerase domain B mutation is associated with hepatitis relapse during long-term lamivudine therapy for chronic hepatitis B.
Nakanishi H; Kurosaki M; Asahina Y; Onuki Y; Ueda K; Nishimura Y; Tsuchiya K; Kitamura T; Uchihara M; Miyake S; Enomoto N; Izumi N
Intervirology; 2005; 48(6):381-8. PubMed ID: 16024942
[TBL] [Abstract][Full Text] [Related]
12. [Detection of YMDD motif mutations in lamivudine-untreated patients with chronic hepatitis B].
Yan MH; Zhang C; Ling Q; Zhou RF
Zhonghua Gan Zang Bing Za Zhi; 2003 Jul; 11(7):430-1. PubMed ID: 12890351
[No Abstract] [Full Text] [Related]
13. [Lamivudine treatment of patients with decompensated HBV cirrhosis and mutation in YMDD motif].
Wei L
Zhonghua Gan Zang Bing Za Zhi; 2005 Jan; 13(1):77-8. PubMed ID: 15670511
[No Abstract] [Full Text] [Related]
14. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping.
Ohishi W; Shirakawa H; Kawakami Y; Kimura S; Kamiyasu M; Tazuma S; Nakanishi T; Chayama K
J Med Virol; 2004 Apr; 72(4):558-65. PubMed ID: 14981758
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and problems in combination therapy using lamivudine and interferon for chronic hepatitis B].
Saito T; Watanabe H; Togashi H; Kawata S
Nihon Rinsho; 2004 Aug; 62 Suppl 8():326-30. PubMed ID: 15453339
[No Abstract] [Full Text] [Related]
16. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine.
Hatakeyama T; Noguchi C; Hiraga N; Mori N; Tsuge M; Imamura M; Takahashi S; Kawakami Y; Fujimoto Y; Ochi H; Abe H; Maekawa T; Kawakami H; Yatsuji H; Aisaka Y; Kohno H; Aimitsu S; Chayama K
Hepatology; 2007 May; 45(5):1179-86. PubMed ID: 17465002
[TBL] [Abstract][Full Text] [Related]
17. Natural YMDD-motif mutants affect clinical course of lamivudine in chronic hepatitis B.
Tan YW; Ye Y; Ge GH; Zhao W; Gan JH; Zhao Y; Niu ZL; Zhang DJ; Chen L; Yu XJ; Yang LJ
World J Gastroenterol; 2015 Feb; 21(7):2089-95. PubMed ID: 25717242
[TBL] [Abstract][Full Text] [Related]
18. YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine.
Matsuda M; Suzuki F; Suzuki Y; Tsubota A; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Satoh J; Kobayashi M; Ikeda K; Miyakawa Y; Kumada H
J Med Virol; 2004 Oct; 74(2):361-6. PubMed ID: 15332287
[TBL] [Abstract][Full Text] [Related]
19. How do naturally occurring YMDD-motif mutants influence the clinical course of lamivudine-naïve patients with chronic hepatitis B virus infection?
Tsubota A
J Gastroenterol Hepatol; 2006 Dec; 21(12):1769-71. PubMed ID: 17074012
[No Abstract] [Full Text] [Related]
20. [Individual therapy for the patients with YMDD mutation in HBV by lamivudine].
Liu Z
Zhonghua Gan Zang Bing Za Zhi; 2003 Sep; 11(9):558. PubMed ID: 14552722
[No Abstract] [Full Text] [Related]
[Next] [New Search]
